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SORT IT SUPPLEMENT: POST-EBOLA RECOVERY IN WEST AFRICA
The Ebola outbreak: effects on HIV reporting, testing and  
care in Bonthe district, rural Sierra Leone
A. H. Gamanga,1 P. Owiti,2,3 P. Bhat,4 A. D. Harries,3,5 I. Kargbo-Labour,6 M. Koroma6
Ebola virus disease is a zoonotic, filovirus infection that is part of a group of diseases known as viral 
haemorrhagic fevers.1 Transmission occurs through 
close contact with the body fluids of infected patients; 
the disease can therefore spread rapidly, especially 
where health systems are fragile and under-resourced.2,3
The 2014 Ebola outbreak in West Africa started in 
Guinea in December 2013 and spread rapidly to Liberia 
and Sierra Leone.4 By 3 January 2016, 28 637 cases had 
been reported in the region, of whom 11 315 were 
known to have died.5 The extent of the outbreak com-
pelled the World Health Organization (WHO) to de-
clare an international public health emergency in 
2014.6 Sierra Leone was the most heavily burdened 
country, with almost half of all cases.5 The outbreak 
started in Sierra Leone in May 2014 and was declared 
over in November 2015, although occasional sporadic 
cases occurred thereafter. Prior to the Ebola outbreak, 
the country was struggling to recover from civil war 
and already had serious deficiencies in its health system 
and considerable health worker shortages.2,7 The Ebola 
outbreak adversely affected the quality of health service 
delivery, and had a major impact on health-seeking be-
haviour and access to care in the community.8,9
In all three countries in the region, including Sierra 
Leone, the outbreak led to disruption of the tuberculo-
sis (TB), human immunodeficiency virus/acquired im-
mune-deficiency syndrome (HIV/AIDS) and malaria 
programmes.10 In Sierra Leone, a large proportion of 
clinics offering services for pregnant women with HIV 
were reported to have closed, as had a large propor-
tion of clinics providing HIV testing and antiretroviral 
therapy (ART), resulting in reported decreases 
throughout the country in the number of people with 
HIV being started and retained on therapy.10 Similar 
problems were reported in neighbouring Guinea.11
The extent and details of the disruption to HIV di-
agnostic and treatment services requires further assess-
ment to prevent this from happening again should 
another Ebola outbreak threaten the health-care sys-
tem and services. A rapid method of assessment is to 
observe whether HIV diagnostic and treatment ser-
vices differed at the district level before and during the 
Ebola epidemic.
Bonthe District, one of 14 medical districts in Sierra 
Leone, is situated in a remote area in the south of the 
country. This was the district least affected by the Eb-
ola outbreak, with only five recorded cases (the first 
on 18 May 2015 and the last on 20 December 2015). 
The measures put in place, i.e., quarantining, re-
stricted travel, a ‘no touch’ policy and repurposing of 
health-care workers, were nevertheless imposed in all 
districts of the country, and we were interested to 
know whether this resulted in disruption of pro-
grammes in a remote district that was not directly or 
severely affected by the outbreak.
The aim of this study was therefore to determine 
whether the diagnosis and treatment of people living 
with HIV, including pregnant women, differed before 
Ebola and during the Ebola outbreak period in the 
Bonthe District of Sierra Leone. Specific objectives 
during the two periods were to document the submis-
sion and completeness of monthly reporting for HIV 
data, the uptake of HIV testing and care for pregnant 
women attending antenatal clinics and HIV testing 
and treatment in the general population.
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Setting: All public health facilities in Bonthe District, ru-
ral Sierra Leone.
Objective: To compare, in the periods before and during 
the Ebola virus disease outbreak, 1) the submission and 
completeness of monthly human immunodeficiency virus 
(HIV) reports, and 2) the uptake of HIV testing and care 
for pregnant women and the general population.
Design: A cross-sectional study using routine pro-
gramme data.
Results: Of the 627 HIV reports expected in each period, 
406 (65%) were submitted in the pre-Ebola period and 
376 (60%) during the Ebola outbreak (P = 0.08), of 
which respectively 318 (78%) and 335 (89%) had com-
plete information (P < 0.001). In the pre-Ebola period, 
5012 pregnant women underwent testing for HIV, of 
whom 25 were HIV-positive, compared to 4254 during 
the Ebola period, of whom 21 were HIV-positive (P < 
0.001). Of those who were HIV-positive, respectively 14 
(56%) and 21 (100%) received antiretroviral prophylaxis 
or antiretroviral therapy (ART) (P < 0.001). In the general 
population, 5770 persons underwent HIV testing pre-Eb-
ola vs. 3095 in the Ebola period (P < 0.001); of those 
who tested positive for HIV, respectively 62% (33/53) 
and 81% (33/41) were started on ART (P = 0.06).
Conclusion: There was suboptimal reporting on HIV/ac-
quired immune-deficiency disease syndrome activities be-
fore and during the Ebola virus disease outbreak. HIV 
testing decreased during the Ebola outbreak, while the 
uptake of prevention of mother-to-child transmission and 
ART increased. Pre-emptive actions are needed to main-
tain the levels of HIV testing in any future outbreak.
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METHODS
Study design
This was a comparative cross-sectional study assessing 
monthly reporting and HIV diagnosis and treatment at 
the district level by the use of routine record systems.
Setting
General setting: country and district
Sierra Leone, a small country in West Africa, with a 
population of approximately 7 million (2015 national 
census),12 is bordered by Guinea and Liberia. Its gross 
national income per capita is US$1340.13 There is an 
established network of public health facilities deliver-
ing health-care services for which the population has 
to pay, except for children aged <5 years, pregnant 
women and lactating mothers, who are covered by the 
free health-care policy, as are patients who are diag-
nosed and treated within disease-specific programmes 
such as those for TB and HIV/AIDS. The public health 
care services are supplemented by the private sector, 
industry-supported clinics and non-governmental or-
ganisations (NGOs), including faith-based facilities.
Bonthe District, situated in a remote area in south-
ern Sierra Leone, is divided into the mainland and the 
islands, with the latter constituting the larger part of 
the district. There are many isolated islands, and these 
are the most remote, hardest-to-reach areas of the 
country. Bonthe District, divided administratively into 
11 chiefdoms and a municipality, has a total popula-
tion of approximately 200 000, of whom 70 000 live on 
Bonthe Island. Health-care delivery is provided by the 
government hospital on the island, a mission hospital 
on the mainland and 55 peripheral health units 
(PHUs) distributed between the island and the main-
land. During the 2014 Ebola epidemic, these health-
care facilities recorded a sharp fall in patient load.
HIV testing and treatment services: national and 
district
The HIV epidemic in Sierra Leone is described as 
mixed, generalised and heterogeneous. The latest data 
(2014) estimated an HIV prevalence of 1.4% in the 
adult population aged 15–49 years, and 55 000 people 
living with HIV/AIDS (PLHIV), of whom 4700 were 
children.14 New HIV infections and AIDS-related 
deaths were estimated at 2700 for the year. ART cover-
age in 2014 was 38%, i.e., 10 289/26 495 PLHIV receiv-
ing ART. Prevention of mother-to-child transmission 
(PMTCT) coverage with antiretroviral (ARV) prophy-
laxis, with either single-dose nevirapine at labour or 
with zidovudine during pregnancy, was much better, 
at 85%, i.e., 2585/3055 women living with HIV receiv-
ing ARV.14
Details of the national response to HIV/AIDS are 
shown in the Table.14–17 In Bonthe District the two 
hospitals and 55 PHUs provide HIV testing and coun-
selling, including for pregnant women, and ARV pro-
phylaxis for pregnant women as part of PMTCT cover-
age. Cotrimoxazole preventive therapy is initiated in 
all persons who are HIV-positive, and recommended 
ART regimens16,17 are offered at the PHUs to pregnant 
women, children and adults in WHO clinical stages 3 
and 4. Asymptomatic adults and those in WHO clini-
cal stages 1 and 2 are referred to the hospitals for CD4 
cell testing to determine their eligibility for ART. Data 
on HIV testing and ART registration are recorded in 
standardised registers (both antenatal care [ANC] and 
general population registers) based at the hospitals or 
PHUs. Monthly reports are sent to the district health 
management team (DHMT), where they are collated 
into monthly summary forms by the Monitoring and 
Evaluation Officers.
Study population
The study population included aggregate numbers of 
persons and pregnant women in Bonthe District who 
were tested for HIV, found to be HIV-positive and 
started on PMTCT and/or ART in the pre-Ebola (1 June 
2013–30 April 2014) and Ebola (1 June 2014–30 April 
2015) periods.
Data variables, sources of data and data 
collection
Data variables included the period, year, month, site 
(PHU or hospital), number of monthly reports submit-
ted and completed, number of pregnant women un-
dergoing HIV testing each month and number testing 
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TABLE The national response to HIV/AIDS in Sierra Leone
National response
The National AIDS Commission and the National AIDS Secretariat provide the leadership and coordination of the HIV/AIDS 
response. The National AIDS Control Programme, within the MoHS, is responsible for implementation of the national 
response, which before and during the Ebola epidemic was guided by the multi-sectoral National Strategic Plan of 2011–
201514
On 1 December 2015, the MoHS launched the 2016 strategy of reducing new HIV infections to zero, in line with the UNAIDS 
90–90–90 strategy15
Guidelines for HIV testing, PMTCT and ART were developed when HIV/AIDS became a problem in the country, and these are 
regularly updated in line with WHO guidance. The country currently uses ‘Option B’ for PMTCT, and both before and during 
the Ebola epidemic the 2010 WHO guidelines were followed for ART initiation based on CD4 cell count < 350 cells/μl and 
WHO clinical staging16,17
Progress in terms of the country’s HIV status (HIV prevalence, new HIV infections and AIDS deaths) and national response (HIV 
testing, PMTCT and ART uptake) are provided by annual national AIDS response progress reports; the latest, published in 
2015, reported data for the previous 2 years14
HIV = human immunodeficiency virus; AIDS = acquired immune-deficiency syndrome; MoHS = Ministry of Health and Sanitation; UNAIDS = Joint 
United Nations Programme on HIV/AIDS; PMTCT = Prevention of Mother-to-Child Transmission; ART = antiretroviral treatment; WHO = World 
Health Organization.
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positive for HIV and administered PMTCT prophylaxis or who 
started ART. In the general population, the data variables were the 
monthly number who underwent HIV testing, tested positive for 
HIV and started ART. The sources were the antenatal registers, 
HIV testing registers and the monthly summary forms at the 
PHUs and the hospitals.
Analysis and statistics
The data were entered into an Excel file (Microsoft Corp, Red-
mond, WA, USA), and exported and analysed using EpiData soft-
ware (v. 2.2.2.182, EpiData Association, Odense, Denmark). A 
submitted monthly report was judged to be complete if it con-
tained the number of patients tested for HIV, the number who 
tested positive for HIV and the number initiated on PMTCT and/
or ART. The means and proportions were analysed and compared 
between the pre-Ebola and the Ebola periods using respectively 
the t-test and the χ2 test, with levels of significance set at 5%.
Ethics approval
Permission to carry out the study was granted by the Ministry of 
Health and Sanitation (MoHS, Freetown, Sierra Leone). Local eth-
ics approval was obtained from the Sierra Leone National Ethics 
Committee (MoHS, Freetown), and international ethics approval 
was provided by the Ethics Advisory Group of the International 
Union Against Tuberculosis and Lung Disease (Paris, France). As 
this was a record review of aggregate data, the need for informed 
patient consent was waived.
RESULTS
Submission and completeness of monthly HIV data
Figure 1 shows the monthly submissions of HIV reports from the 
57 health facilities and whether the reports had complete infor-
mation in the pre-Ebola and the Ebola periods. Of the expected 
627 reports for each 11-month period, 406 (65%) were submitted 
in the pre-Ebola period; this was not very different from the 376 
(60%) submitted in the Ebola period (P = 0.08). Of the submitted 
reports, in the pre-Ebola period 318 (78%) had complete informa-
tion, significantly fewer than the 335 (89%) in the Ebola period (P 
< 0.001).
HIV testing and care for pregnant women
Figure 2A shows the monthly HIV testing rates in pregnant 
women attending antenatal clinics in the pre-Ebola and Ebola pe-
riods. In the pre-Ebola period, 5012 pregnant women were tested 
for HIV (monthly mean 456, standard deviation [SD] 69), com-
pared to 4254 in the Ebola period (monthly mean 425, SD 84); 
these differences were statistically significant (P < 0.001). Figure 
2B shows the monthly uptake of PMTCT/ART in HIV-infected 
pregnant women. Respectively 25 (<1%) and 21 (<1%) pregnant 
women tested positive for HIV in the pre-Ebola and Ebola peri-
ods. In the pre-Ebola period, 56% (14/25) were given PMTCT/ART 
compared with 100% of the women in the Ebola period (P < 
0.001).
HIV testing and treatment in the general population
Figure 3A shows the monthly HIV testing rates in the general pop-
ulation (excluding pregnant women) in the pre-Ebola and Ebola 
periods. In the pre-Ebola period, a total of 5770 persons were 
tested for HIV (monthly mean 577, SD 103) compared to 3095 in 
the Ebola period (monthly mean 310, SD 78); these differences 
were statistically significant (P < 0.001). Figure 3B shows the 
monthly initiation rates of ART in HIV-positive patients. In the 
pre-Ebola and the Ebola periods, respectively 53 and 41 persons 
tested positive for HIV. Of these, 62% (33/53) were started on ART 
in the pre-Ebola period, which was not significantly different from 
the 81% (33/41) started on ART in the Ebola period (P = 0.06).
DISCUSSION
This is the first study to report on the effects of the Ebola out-
break on HIV testing and care services in the general population, 
including pregnant women, in a remote, hard-to-reach district of 
Sierra Leone. It is also among the first studies to report on the 
submission and completeness of HIV data in this region.
There were some interesting findings. First, the monthly re-
porting rates for HIV were generally low in this district during the 
two periods, with over one third of reports not submitted. The 
completeness of the submitted reports improved during the Ebola 
outbreak, however. Second, HIV testing rates dropped in the Eb-
FIGURE 1 Submission of monthly HIV reports and their completeness in Bonthe District, Sierra Leone, before and 
during the Ebola disease outbreak, 2013–2015. Pre-Ebola period = 1 June 2013–30 April 2014; Ebola period = 1 June 
2014–30 April 2015. There were no data for any of the health facilities in December 2014. HIV = human immunodefi-
ciency virus.
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ola outbreak period, in both the general population and pregnant 
women. Conversely, uptake of ART and/or PMTCT services for 
PLHIV, including pregnant women, increased in the Ebola period.
A key strength of this study is that as it included all the public 
health facilities in the district, it is a good representation of the 
whole district. Furthermore, the conduct and reporting of the 
study adhered to the STrengthening the Reporting of OBserva-
tional Studies in Epidemiology (STROBE) guidelines and sound 
ethics principles.18,19
There were several limitations to the study. No data were avail-
able for any of the health facilities for December 2014, while no 
data were available for HIV care services for the general popula-
tion for December 2013. The monthly reports indicated the num-
ber of persons undergoing HIV testing, but did not provide reli-
able information either on the number of pregnant women or on 
the number in the general population who were eligible for HIV 
testing, and thus the proportions being HIV tested could not be 
ascertained. The study was based on routine programme records, 
which often suffer from issues of data quality. There was also no 
information in the various registers examined about the eligibility 
criteria for ART uptake in assessing treatment uptake in PLHIV in 
the general population.
Previous studies have highlighted the disruption of HIV, TB 
and malaria programmes as a result of the Ebola outbreak in the 
region.10 In particular, the closure of clinics may have led to de-
clines in the number of persons tested for HIV and/or initiated 
and maintained on treatment and care. This was likely due to the 
repurposing of resources, including health-care workers, to the 
hard hit regions. Bonthe District reported only five of the 14 122 
Ebola cases in the country, and no facilities were closed during 
the Ebola outbreak. While there was no official redeployment of 
the health workforce from Bonthe to other districts, more than 
half of the workforce consisted of volunteers, who were not as re-
stricted in their movements as others. These volunteers also of-
fered HIV testing services. In addition to the lack of trust between 
community and health workforce, there was a ‘no touch’ policy 
implemented in the district, in compliance with recommenda-
tions for the country as a whole, and there was also a general dis-
FIGURE 2 HIV testing and PMTCT/ART interventions in pregnant women attending antenatal clinics in Bonthe 
District, Sierra Leone, before and during the Ebola outbreak period, 2013–2015. A) Numbers of pregnant women 
tested for HIV. B) HIV-positive pregnant women started on ART or given PMTCT. No pregnant woman tested posi-
tive for HIV in the months of July and September 2014 and March 2015. There were no data for any of the health 
facilities in December 2014. Pre-Ebola period = 1 June 2013–30 April 2014; Ebola period = 1 June 2014–30 April 
2015. HIV = human immunodeficiency virus; PMTCT = Prevention of Mother-to-Child Transmission; ART = antiretro-
viral therapy.
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couragement of HIV testing using the fingerprick test.20 These fac-
tors are likely to have contributed to the reduced testing rates for 
HIV in the population during the Ebola outbreak.20
The increased uptake of ART in the Ebola outbreak was reassuring. 
This may have been due to active uptake of ART by patients due to 
the fear that any exacerbation or worsening of their condition could 
be misinterpreted as Ebola. The national policy that restricted the 
movement of people between districts may also have assisted in the 
initiation and retention of HIV patients on care within the district.
Two main implications arise from this study. First, measures 
are needed to ensure regular, comprehensive reporting and com-
pleteness of health data, including for HIV. This includes improv-
ing the quantity and quality of the health workforce responsible 
for data monitoring and encouraging retention strategies, train-
ing, regular supervision, feedback and strategic use of the data. 
Constant availability of data collection and reporting tools is also 
key, and consideration should be given to setting up and deploy-
ing electronic medical record systems at district level. One model 
could be the robust, point-of-care touch screen electronic medical 
record system that has been successfully scaled up in Malawi.21
Second, pre-emptive measures are needed to mitigate the ne-
glect of disease control programmes, including HIV, in the event 
of future outbreaks. These include planning for and ensuring 
safety measures and an adequate supply of logistics and resources, 
including those that can be provided by the donor community.20 
Programmes need to be innovative. HIV testing methods other 
than the fingerprick test need to be considered, such as oral sali-
vary testing and using established community-based testing ap-
proaches.22,23 A study in neighbouring Guinea showed that TB 
control services could be maintained during an Ebola outbreak 
provided there is contingency planning that includes support for 
the health systems, services and health-care workers.24 
Sierra Leone was declared free of Ebola on 7 November 2015, 
and although there have been occasional sporadic cases since that 
date, the road to recovery has begun. Recovery measures have to 
address those problems that existed even before the outbreak, in-
cluding the data and reporting systems. This study has shown that 
reporting rates for HIV data were low even in the pre-Ebola period, 
while during the Ebola outbreak testing for HIV decreased both in 
the general population and in pregnant women. Pre-emptive ac-
tions are needed to maintain HIV testing rates in future outbreaks.
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Contexte  :  Toutes les structures de santé publiques du district de 
Bonthe, Sierra Leone rurale.
Objectif  :  Au cours des périodes avant et pendant l’épidémie d’Ebola, 
comparer 1) la soumission et la complétude des rapports mensuels 
du virus de l’immunodéficience humaine (VIH), et 2) la couverture du 
test VIH et les soins des femmes enceintes et de la population 
générale.
Schéma  :  Étude transversale grâce à des données de routine du 
programme.
Résultats  :  Sur les 627 rapports relatifs au VIH attendus pour chaque 
période, 406 (65%) ont été soumis avant Ebola et 376 (60%) 
pendant l’épidémie d’Ebola (P = 0,08) ; 318 (78%) des rapports pré 
Ebola et 335 (89%) des rapports de la période Ebola comportaient 
des informations complètes (P < 0,001). Dans la période pré-Ebola, 
5012 femmes enceintes ont eu un test VIH (dont 25 VIH positives) 
comparées aux 4254 (dont 21 VIH positives) pendant Ebola (P < 
0,001), et parmi les femmes VIH positives, respectivement 14 (56%) 
et 21 (100%) ont reçu une prophylaxie antirétrovirale ou un 
traitement antirétroviral (TAR) (P < 0,001). Dans la population 
générale, 5770 personnes ont été testées pour le VIH avant Ebola et 
3095 pendant Ebola (P < 0,001). Parmi les personnes VIH positives, 
respectivement 62% (33/ 53) et 81% (33/ 41) ont mis en route un 
TAR avant et pendant Ebola (P = 0,06).
Conclusion  :  Les rapports relatifs aux activités VIH/SIDA (syndrome 
de l’immunodéficience acquise) avant et après l’épidémie d’Ebola ont 
été sous-optimaux. La couverture du test VIH a diminué pendant 
l’épidémie d’Ebola, tandis que la couverture de la prévention de la 
transmission mère-enfant et TAR a augmenté. Des efforts de 
prévention sont requis pour maintenir l’utilisation du test VIH dans 
toute épidémie à venir.
Marco de referencia: Todos los establecimientos públicos de 
atención de salud del distrito Bonthe en una zona rural de Sierra 
Leona.
Objetivo: Al analizar el período anterior a la epidemia de fiebre 
hemorrágica del Ébola y el período epidémico, se compararon los 
siguientes aspectos: 1) la rendición de informes mensuales sobre el 
virus de la inmunodeficiencia humana (VIH) y su integridad; y 2) la 
aceptación de las pruebas diagnósticas de la infección por el VIH y la 
adhesión al tratamiento por parte de las embarazadas y la población 
general.
Método: Un estudio transversal a partir de los datos corrientes del 
programa.
Resultados: De los 627 informes sobre el VIH previstos en cada 
período, antes de la epidemia del Ébola se enviaron 406 informes 
(65%) y durante la misma 376 (60%; P = 0,08); la información 
transmitida fue completa en 318 informes anteriores a la epidemia 
(78%) y en 335 de los informes presentados durante el brote (89%; P < 
0,001). Antes de la epidemia del Ébola se practicó la prueba del VIH a 
5012 embarazadas (25 resultados positivos), en comparación con 4254 
durante la epidemia (21 resultados positivos; P < 0,001); antes del 
brote, de las pacientes con resultado positivo, 14 recibieron profilaxis o 
tratamiento con medicamentos antirretrovíricos (TAR) (56%) y 21 
pacientes durante epidemia (100%; P < 0,001). En la población 
general, antes del brote del Ébola se practicó la prueba del VIH a 5770 
personas y durante la epidemia a 3095 personas (P < 0,001). De las 
personas positivas frente al VIH antes del brote, el 62% inició el TAR (33 
de 53) y el 81% durante la epidemia (33 de 41; P = 0,06).
Conclusión: Se constató una deficiencia en la notificación de las 
actividades de atención del VIH/sida antes del brote epidémico y 
durante el mismo. La realización de pruebas diagnósticas del VIH 
disminuyó durante la epidemia, pero aumentó la administración del 
TAR y la prevención de la transmisión madre al niño. Se precisan 
medidas anticipatorias que permitan conservar la tasa de utilización 
de la prueba del VIH durante todo episodio epidémico futuro.
